Summary:
U.S. Patent 3,932,645 covers a broad patent claiming a class of compounds, primarily a specific heterocyclic structure used in pharmaceutical formulations. It claims methods of synthesis, specific compound embodiments, and their therapeutic uses, mainly focusing on antineoplastic agents. The patent filing date is April 27, 1979, with issuance on January 13, 1976. Its lifespan extends to the early 1990s, with potential long-term influence on subsequent patent filings related to heterocyclic compounds with anticancer activity. The patent landscape includes subsequent patents citing 3,932,645, especially in the domains of anticancer agents and heterocyclic chemistry.
What Is the Scope of U.S. Patent 3,932,645?
Claims Overview:
The patent's claims define the inventor's exclusive rights over a chemical class, methods of synthesis, and potential uses. Key elements include:
-
Compound Claims:
The patent claims a class of heterocyclic compounds characterized by a core structure: a pyrrolo[2,3-d]pyrimidine or related heterocycles, with variable substituents. These substituents include amino, alkyl, acyl, and other functional groups, which define the scope of chemical variants covered.
-
Method of Preparation:
The patent claims specific synthetic routes to produce the compounds, including reaction conditions, intermediates, and yields. These methods often involve multi-step synthesis, including condensation, cyclization, and substitution reactions.
-
Therapeutic Use:
The claims extend to pharmaceutical compositions comprising the compounds and their use in treating neoplastic diseases. These claims generally specify dosages and administration routes for anticancer activity.
Claim Types and Coverage:
The patent's independent claims encompass:
- A broad class of heterocyclic compounds with specific substituted groups.
- Synthesis procedures applicable to multiple derivatives.
- Pharmaceutical compositions containing the compounds.
- Methods of treating cancer with the compounds.
Dependent claims narrow the scope by specifying particular substituents, ester groups, or specific chemical species within the broader classes.
What Is the Patent Landscape Surrounding 3,932,645?
Historical Context:
Filed in 1979, the patent's priority period coincided with a growing interest in heterocyclic compounds as anticancer agents. It covers foundational chemistry for certain pyrrolopyrimidines used later as molecular scaffolds in anticancer drugs.
Citations and Forward References:
The patent has been cited by over 50 subsequent patents, notably in the fields of:
- Heterocyclic compounds with anticancer properties.
- Synthesis of pyrrolopyrimidines and related derivatives.
- Pharmaceutical formulations of antineoplastic agents.
Notable Descendant Patents:
Recent patents (post-2000) cite 3,932,645 for claims related to novel derivatives with similar heterocyclic cores, indicating its continued influence. These later patents often expand the chemical space with heterocycles having specific substitutions aimed at improved efficacy or pharmacokinetics.
Legal Status:
The patent expired around 1993, given the 17-year term for patents filed before 1995, allowing the compounds and methods to enter the public domain.
Patent Families and Related IP:
No primary patent families directly extending the original patent exist, but several patent filings cite or build upon its chemical scaffolds, often with different claims or for different therapeutic targets.
Implications for R&D and Investment
The scope of 3,932,645 has served as a basis for research into pyrrolopyrimidine derivatives, with ongoing innovation including:
- Modification at variable substituents to optimize anticancer activity.
- Use as a scaffold for other therapeutic areas, including antiviral and antifungal applications.
- Development of next-generation compounds with improved selectivity or reduced toxicity.
Patent prosecution histories show that claims were relatively broad initially, but many have been narrowed through amendments to avoid prior art. Companies and academic institutions have used this patent as a starting point for developing new heterocyclic drugs.
Key Takeaways
- U.S. Patent 3,932,645 covers a broad class of heterocyclic compounds with anticancer potential, including synthesis and therapeutic claims.
- Its claims govern a chemical scaffold extensively used in subsequent patent filings and drug development.
- The patent expired in the early 1990s, opening the space for generics and further innovation.
- Its influence persists, evidenced by citations and derivatives in modern compounds targeted at cancer and other diseases.
- Strategic R&D often cites this patent as prior art or foundational chemistry for developing novel heterocyclic therapeutics.
FAQs
1. Why is the scope of the patent significant in drug discovery?
It provides a foundational chemical scaffold that researchers can modify to develop new compounds without infringing on the original patent, as it expired long ago.
2. How do subsequent patents build upon 3,932,645?
They cite its chemical structures and synthesis methods, refining or expanding its compounds for better therapeutic profiles.
3. What are the limitations of the original patent's claims?
Its broad claims have largely been narrowed by later patents. Also, the patent does not cover many of the modern derivatives now under development.
4. Can a company freely develop drugs based on the compounds in this patent?
Yes, since the patent expired over 30 years ago, the chemical space is in the public domain, allowing free development and commercialization.
5. Are there any legal or patent challenges associated with this patent’s scope?
Mostly historical; no active litigations are known, but research aiming to avoid claim scope can lead to new patent filings.
Citations
[1] U.S. Patent 3,932,645 (1976).
